Positive News SentimentPositive NewsNASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $5.50 -0.38 (-6.46%) Closing price 04:00 PM EasternExtended Trading$5.50 +0.00 (+0.09%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PHAT alerts:Sign Up Key Stats Today's Range$5.47▼$5.9550-Day Range$5.08▼$9.4352-Week Range$5.01▼$18.31Volume1.06 million shsAverage Volume1.31 million shsMarket Capitalization$447.10 millionP/E RatioN/ADividend YieldN/APrice Target$20.11Consensus RatingModerate Buy Company Overview Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 2018, the company is based in Florham Park, New Jersey, and concentrates its commercial activities on the U.S. market. Its primary product is Voquezna (vonoprazan), an acid blocker used to treat certain conditions involving gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD. Vonoprazan is also used with antibiotics to treat Helicobacter pylori infection. Vonoprazan belongs to a class of medicines called potassium-competitive acid blockers, which reduce stomach acid. Phathom’s work centers on making this treatment available for approved gastrointestinal indications and advancing its use in acid-related diseases.AI Generated. May Contain Errors. Read More Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePHAT MarketRank™: 3.731600583475 of 5 starsPhathom Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 150th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPhathom Pharmaceuticals has a consensus price target of $20.11, representing about 265.7% upside from its current price of $5.50.Amount of Analyst CoveragePhathom Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($0.31) to $1.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.49% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 4.83.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 5.93%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentPhathom Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.Search InterestOnly 2 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders9.33% of the stock of Phathom Pharmaceuticals is held by insiders.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAT Stock News HeadlinesWhat Phathom Pharmaceuticals Bears Spotted Before A 63% SlideNovember 4, 2026 | finance.yahoo.comPhathom Pharmaceuticals to Participate in November Investor ConferencesNovember 4, 2026 | globenewswire.comDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.November 17 at 1:00 AM | TradeWins (Ad)Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRxNovember 3, 2026 | globenewswire.comPhathom Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 2, 2026 | seekingalpha.comPhathom Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full Year 2026October 30, 2026 | marketscreener.comMPhathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 OutlookOctober 29, 2026 | rttnews.comPhathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 29, 2026 | marketscreener.comMSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $16.59 at the start of the year. Since then, PHAT stock has decreased by 66.8% and is now trading at $5.50. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its earnings results on Thursday, February, 26th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.44 million. Read the conference call transcript. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $182 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 9,563,157 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Top institutional shareholders of Phathom Pharmaceuticals include GW&K Investment Management LLC (2.62%), State Street Corp (2.46%), Catalys Pacific LLC (2.33%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh, Molly Henderson, James N Topper, Frank Karbe and Robert Charles Breedlove. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include NVIDIA (NVDA), Plug Power (PLUG), Tesla (TSLA), Palantir Technologies (PLTR), Ardelyx (ARDX), Definium Therapeutics (DFTX) and Cassava Sciences (FLNA). Company Calendar Today11/17/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PHAT's financial health is in the Red zone, according to TradeSmith. PHAT has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PHAT CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees371Year Founded2018Price Target and Rating Average Price Target for Phathom Pharmaceuticals$20.11 High Price Target$28.00 Low Price Target$10.00 Potential Upside/Downside+265.7%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E Ratio4.95 P/E GrowthN/ANet Income-$221.25 million Net Margins-30.19% Pretax Margin-30.19% Return on EquityN/A Return on Assets-13.38% Debt Debt-to-Equity RatioN/A Current Ratio1.76 Quick Ratio1.72 Sales & Book Value Annual Sales$175.11 million Price / Sales2.55 Cash FlowN/A Price / Cash FlowN/A Book Value($4.28) per share Price / Book-1.29Miscellaneous Outstanding Shares81,290,000Free Float73,707,000Market Cap$447.10 million OptionableOptionable Beta0.69 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PHAT) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.